A new report from the Institute of Medicine (IOM) recommends that 8 preventive health services for women will be added to the services that health plans will cover at no cost to patients under the Patient Protection and Affordable Care Act of 2010 (PPACA).
A new report from the Institute of Medicine (IOM) recommends that 8 preventive health services for women be added to the services that health plans will cover at no cost to patients under the Patient Protection and Affordable Care Act of 2010 (ACA).
The ACA requires plans to cover the services listed in the U.S. Department of Health and Human Services' (HHS) comprehensive list of preventive services. At the agency's request, an IOM committee identified critical gaps in preventive services for women as well as measures that will further ensure women's health and well-being.
The recommendations are based on a review of existing guidelines and an assessment of the evidence on the effectiveness of different preventive services. The committee identified diseases and conditions that are more common or more serious in women than in men or for which women experience different outcomes or benefit from different interventions. The report suggests the following additional services:
• Screening for gestational diabetes
• Human papillomavirus (HPV) testing as part of cervical cancer screening for women over aged 30
• Counseling on sexually transmitted infections
• Counseling and screening for HIV
• Contraceptive methods and counseling to prevent unintended pregnancies
• Lactation counseling and equipment to promote breast-feeding
• Screening and counseling to detect and prevent interpersonal and domestic violence
• Yearly well-woman preventive care visits to obtain recommended preventive services
“These latest recommendations from the IOM should be welcomed and applauded by our healthcare industry given the well-recognized outcomes which may be derived from greater access to such services,” said David Calabrese, vice president, Clinical Operations, MedMetrics Health Partners, an SXC Company.
For example, the health and financial impact of intimate partner violence (IPV) is vast and widespread, indicating that any plan designed to strengthen screening and intervention efforts is a welcome addition, said Jeff R. Temple, PhD, an assistant professor and psychologist in the department of obstetrics and gynecology at University of Texas Medical Department (UTMB Health), Galveston, Texas. Indeed, a report by the Centers for Disease Control and Prevention estimated that IPV results in more than $4 billion a year in healthcare services.
“However, given recent research showing that screening for IPV may not, in and of itself, result in improved violence outcomes, a concomitant investment should also be made in enhancing the quality, availability, and utilization of services offered to abused women,” Temple told Drug Topics.
“A concerted effort should be made to prevent potential early predictors of intimate partner violence, such as bullying and teen dating violence. While initially costly, attending to these abusive behaviors in our youth would not only result in healthier adult relationships, but would have the potential to save a substantial amount of healthcare dollars in the long run,” he said. “Further, we should not overlook the role of perpetrators. Efforts to screen and offer evidenced-based interventions to men and women who commit acts of partner violence should be strengthened.”
“From a pharmacy perspective, our nation's pharmacists are once again in an ideal position to assist in reinforcing these efforts, as many are focused in areas of women's health that are familiar to our profession,” Calabrese added. “We also have the greatest degree of direct interaction with the patient community, thus providing yet another opportunity for us to demonstrate our value in further driving a higher-quality, more cost-efficient healthcare system for all."
HHS's guidelines on preventive health services for women will need to be updated routinely in light of new science. As part of this process, the report said that HHS should establish a commission to recommend which services health plans should cover. The commission should be separate from the groups that assess evidence of health services' effectiveness, and it should consider cost-effectiveness analyses, evidence reviews, and other information to make coverage recommendations.
The report addresses concerns that the current guidelines on preventive services contain gaps when it comes to women's needs. Women suffer disproportionate rates of chronic disease and disability from some conditions. Because they need to use more preventive care than men on average due to reproductive and gender-specific conditions, they face higher out-of-pocket costs, the report noted.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More